Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

By K. Herold, W. Hagopian, J. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. Gitelman, D. Harlan, Danlin Xu, R. Zivin and 1 more. New England Journal of Medicine, 2002

622 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Immunology

View Paper: https://www.semanticscholar.org/paper/4412c34a4971705d06d59444be06584364e678bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. A. Michels
2. Mark Atkinson
3. G. Eisenbarth

In Genetics

1. A. Michels
2. Mark Atkinson
3. G. Eisenbarth
4. A. Chan
5. P. Carter

In Immunology

1. P. Carter

Citations in the corpus

• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Therapeutic antibodies that bind cell surface antigens can also transmit intracellular signals required for clinical efficacy and/or contribute to adverse event”
• Type 1 diabetes (2013, background): “These results include an intervention with the anti-CD3 monoclonal antibodies teplizumab ( A ) [ 21 ] and otelixizumab ( B ) [ 22 ] , the anti-CD20 monoclonal antibody rituximab ( C ) [ 23 ] , and a GAD vaccine ( D ) [ 24 ] .”